Cite
HARVARD Citation
Muccino, D. et al. (2020). Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough. ERJ open research. 6 (4), p. . [Online].